XMRV-Positive Patients Respond Well to Ampligen Treatment

There was a 40-week trial using the drug Ampligen to treat XMRV-positive tested patients.  Only severely debilitated patients were selected for this study.   Below is an excerpt from ProHealth and the link to the rest of the article on the study:

Retrovirus antibody positive CFS patients show response to Ampligen®, an experimental therapeutic, relative to XMRV negative group.

Hemispherx Biopharma, Inc. [presented] new clinical data(1) on the possible inter-relationships of XMRV positivity/chronic fatigue syndrome/Ampligen® responsiveness at the 1st International Workshop on XMRV held at the National Institutes of Health in Bethesda, MD, on September 7 and 8, 2010.

CFS is a severe disorder consisting of profound fatigue and a variety of other debilitating symptoms that affects up to 4 million Americans. Recently, DNA was identified from a human gamma retrovirus (XMRV) in 67% of CFS subjects. Evidence also suggested that approximately 50% of the CFS subjects mounted a specific antibody response against XMRV.

Source:  XMRV-Positive Patient Responses to Ampligen® †40-Week Trial Reported Sep 8 at XMRV Workshop